Newly Diagnosed?
GCS Resources
Connect with a Physician
Community Forums

What is Gynecological Carcinosarcoma?

Gynecological Carcinosarcoma (GCS) is a rare and aggressive cancer found primarily in the ovaries and uterus and can also originate in the fallopian tubes and vagina. GCS, is also known as MMMT or malignant mixed Müllerian tumor. Carcinosarcoma is unique in that it contains two types of cells; carcinomatous (epithelial tissue) and sarcomatous (connective tissue). GCS is rare. Fewer than 1,000 cases of GCS are diagnosed each year. Because carcinosarcoma is so rare, there has been limited research or clinical trials that focus on GCS. Unfortunately, this is where the cures will be found. Little or no research results in no cures or effective treatments for us. In order for us to have a fighting chance, we must aggressively support new and ongoing research so that Not One More Woman Will Die from this rotten cancer.

Are You A Candidate for Clinical Trials?

Identifying and supporting GCS specific clinical trials is a major component of our mission.

Learn More

Get Involved

Join this amazing community providing hope, answers, resources & support!
Register
GCS Stories
Help Build Our Experts Knowledge Base

GCS News

The latest news and most engaged discussions from our website.
Surviving treatment

1yr6mths out of treatment Just have found this website So sorry about Ms. Redingtons passing I’m contacting this group In the hopes it survived In my case my family would have treasured your hope suggestions and acknowledgement of this cancer. Mine is a message of hope and encouragement and confusion. Alone is how it felt […]

My Mom: Uterine CS, InfiniteMD, Dr. Birrer

Hi All, I hope this message finds you in good health and good spirits. I wanted to share my mom’s experience in case it helps someone in the future. In 2020 she was diagnosed with uterine CS following a hysterectomy for what was assumed to be a more common cancer. We are tremendously grateful that […]

Study of Rebastinib + Paclitaxel Combination

A Phase 1b/2, Open Label Study of Rebastinib + Paclitaxel Combination for Patients with Advanced or Metastatic Solid Tumors NCT03601897 is a 2-part open label, Phase 1b/2, multicenter study of Rebastinib (DCC-2036), a novel tyrosine switch control inhibitor, orally administered in combination with Paclitaxel. Part 1 evaluated two doses of rebastinib at 50 and 100 […]

View More